Kiora Pharmaceuticals Licenses South Korean Ophthalmic Development and Commercialization Rights for KIO-301 to Chong Kun Dang Pharmaceutical CorporationNewsfile Corp · Aug 19, 2026
Kiora Pharmaceuticals Reports Second Quarter 2026 Financial Results and Provides Corporate UpdateNewsfile Corp · Aug 7, 2026Kiora Pharmaceuticals, Inc., a specialty pharmaceutical firm operating at the clinical stage, is dedicated to the creation and commercialization of treatments for various ophthalmic conditions across the United States. Its flagship therapeutic candidate, KIO-301, is a groundbreaking small molecule undergoing Phase 1 clinical trials. This innovative "photoswitch" aims to revitalize vision in individuals suffering from both inherited and age-related forms of retinal degeneration.
| Date | Est. | Actual | |
|---|---|---|---|
| Aug 7, 2026 | -$0.47 | -$0.34 | Beat |
| May 8, 2026 | -$0.71 | -$0.58 | Beat |
| Mar 25, 2026 | -$0.67 | -$1.60 | Miss |
| Nov 7, 2025 | -$0.72 | $0.01 | Beat |
| Aug 8, 2025 | -$0.58 | -$0.54 | Beat |
| May 9, 2025 | -$0.77 | -$0.52 | Beat |